Graft Versus Host Disease
Recently Identified Biomarkers Found to Warn of Chronic Graft-vs-Host Disease in Marrow Transplant PatientsJuly 01, 2016
Researchers recently identified CXCL10, a protein that could act as a biomarker for chronic graft-versus-host disease (cGVHD), a long-term adverse effect that develops in some patients after undergoing blood and bone marrow transplant.
Corticosteroid Prophylaxis Reduces Risk of Graft-versus-host Disease in Patients Undergoing Haploidentical TransplantationApril 25, 2016
Prophylactic low-dose corticosteroid was significantly associated with relatively low risk of GVHD grades II to IV and rapid platelet recovery in patients undergoing haploidentical transplantation.
A short-chain fatty acid made by bacteria in the gut could play an important role in GVHD after allogeneic bone marrow transplant in mice. In human patients who receive bone marrow transplants, GVHD can cause severe gut damage.
Results for patients with acute leukemia that received the antibody showed lower incidence of chronic graft-versus-host disease post-transplant.
Rejection seen with high-expression allele recipient, low-expression allele donor in HLA-DPB1 mismatches
A new test can assist in the treatment of patients with graft-versus-host disease (GVHD), an often life-threatening complication of bone marrow and stem cell transplants.
A new test may reveal which patients will respond to treatment for graft-versus-host disease (GVHD), a serious complication that can arise from stem cell SCT.
A short course of cyclophosphamide can not only prevent a life-threatening immune response in some bone marrow transplant recipients, but also can eliminate need for the typical 6-month round of immune suppression medicines.
A simple questionnaire that rates breathing difficulties on a scale of 0 to 3 predicts survival in chronic graft-vs-host disease, according to a new study.
Adding bortezomib to standard preventive therapy for GVHD results in improved outcomes for patients receiving stem cell transplants from mismatched and unrelated donors, according to research presented at the 2013 ASH Annual Meeting, in New Orleans.
A new class of drugs reduced the risk of patients contracting a serious and often deadly side effect of lifesaving bone marrow transplant treatments, according to a new study from researchers.
The chemotherapy drug cyclophosphamide prevents graft-versus-host (GVHD) disease in people who receive bone marrow transplants through an immune system cell that evades the toxic effects of cyclophosphamide.
T cells overexpressing the TRAIL protein destroyed graft-versus-host disease caused by stem cell transplant for leukemia and other cancers.
Specially treated T cells infused into high-risk and relapsed leukemia patients can prolong survival after stem cell transplantation.
An experimental drug combination for preventing graft-versus-host disease was not significantly better than the standard regimen on key end points.
Vorinostat, already used in lymphoma, reduces the risk of graft-versus-host disease after allogeneic hematopoietic stem-cell transplantation.
Among patients who receive either peripheral blood stem cells (PBMCs) or bone marrow from unrelated donors, the incidence of overall chronic graft-versus-host-disease (GVHD; 53%) is higher in those who received PBMCs than in those who received bone marrow stem cells (40%).
The CD20 antagonist is a potentially effective preventive and treatment for this common adverse effect of hematopoietic stem cell transplantation.
An HIV drug helped lower the risk of graft-versus-host disease in persons with blood cancer who had stem-cell transplants to rebuild bone marrow.
A regimen using minimal-intensity radiation therapy before bone marrow or stem cell transplantation may work for older patients who cannot tolerate stronger pretransplant treatment.
Scientists have improved a method for bone marrow transplantation from mismatched donors that would help restore the immune system quicker, according to findings presented at the American Society of Hematology Annual Meeting and Exposition in New Orleans in December.
- Novel Blood Test Detects Cancer, Locates Tumor Without Invasive Procedures
- Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer
- Shorter Treatment of Breast Cancer with Trastuzumab May Lead to Improved Results
- Colorectal Cancer Rates Increased Sharply Among Generation X and Millennials
- Pneumonia Associated With Common Cold May Cause Fatal Illness in Stem Cell Transplant Recipients
- Early Palliative Care Reduced ICU Use in Patients With Advanced Cancer
- Ginger Extract Raises Antioxidant Levels in Patients Undergoing Chemotherapy
- Nurse Navigators Improve Physician Engagement in Pretreatment Discussions
- Screening Increases Early Palliative Care, Reduces Aggressive EOL Measures
- Antiperspirants/Deodorants and Breast Cancer (Fact Sheet)
- Genome Sequencing Explains Resistance to CTLA-4 and PD-1 Inhibitors in Metastatic Melanoma
- Lifestyle Choices Have Greater Influence on Colon and Rectal Cancer Risk
- Kidney Cancer Metastases in Lung May Hide Undiagnosed Primary Lung Cancer
- Nasal Biomarker in Smokers Could Predict Lung Cancer
- Arm Lymphoscintigraphy After Axillary Lymph Node Dissection or Sentinel Lymph Node Biopsy in Breast Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|